Filing summary
Identity and period: The supplied filing is Salarius Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing identified as Decoy Therapeutics Inc. Investors should confirm the intended issuer before relying on this summary.
Business context
Salarius is a clinical-stage biopharmaceutical company developing cancer treatments, including seclidemstat (SP-2577), an LSD1 inhibitor. It had no approved products and generated no product-sales revenue; reported revenue came solely from the Cancer Prevention and Research Institute of Texas (CPRIT) grant.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 or comparison |
|---|---|---|
| Grant revenue | $1.27 million | $1.13 million; up 12% |
| Research and development expense | $1.74 million | $1.64 million; up 6% |
| General and administrative expense | $1.33 million | $1.86 million; down 28% |
| Net loss | $1.85 million | $2.08 million |
| Basic and diluted loss per share | $0.06 | $0.22 |
| Operating cash used | $2.72 million | $3.71 million |
| Cash and cash equivalents at quarter-end | $36.61 million | $11.12 million at Dec. 31, 2020 |
| Working capital at quarter-end | $39.7 million | Not stated for the comparable period |
| Total liabilities at quarter-end | $1.99 million | $2.77 million at Dec. 31, 2020 |
Financing activities provided $28.22 million, principally from equity sales and warrant exercises. The company reported $191,395 of note payable at quarter-end. Gross margin is not a meaningful disclosed measure for this grant-funded, pre-commercial business; the filing does not provide a clear value.
Material changes and developments
- Net loss narrowed by $231,920 year over year. Lower general and administrative expense more than offset increased R&D expense and the year-over-year swing in warrant fair-value changes.
- Q1 equity issuance generated approximately $27.0 million in net proceeds, and warrant exercises generated approximately $1.5 million. Common shares outstanding rose to 44,734,328 at March 31, from 23,808,546 at year-end 2020.
- The company completed dose escalation in its Phase 1/2 Ewing sarcoma study and planned an expansion that included Ewing-related, FET-rearranged sarcomas. Its advanced solid tumor study remained in dose escalation.
- CPRIT funding received totaled $11.3 million. Approximately $2.6 million of the remaining $7.4 million grant related to a prostate cancer study the company elected not to pursue and would therefore no longer be available. The grant was extended through November 30, 2021.
Outlook, risks, and contingencies
Management said cash on hand and expected CPRIT funds were expected to support anticipated operating and capital requirements through completion of current clinical trials in 2022 and beyond, while also stating that substantial additional capital would be needed to continue operations and development. Future financing was not assured; equity financing could dilute shareholders, and debt or collaborations could impose restrictions or require relinquishing rights.
The company expected continued losses and rising expenses, with no product revenue anticipated unless and until a candidate receives regulatory approval and is commercialized. It cited risks of clinical development, financing access, CPRIT funding conditions, and potential COVID-19 effects on enrollment, suppliers, operations, and capital markets. It reported minimal COVID-19 disruption to date but warned that future impact was uncertain. The company stated that disclosure controls were effective and reported no material legal proceedings or significant subsequent events requiring disclosure.
Important facts to verify
- Confirm that Salarius Pharmaceuticals, Inc., rather than Decoy Therapeutics Inc., is the intended filing issuer.
- Check current cash runway assumptions against actual trial spending, future financing needs, and CPRIT funds remaining and accessible.
- Verify subsequent clinical-trial progress, data timing, enrollment, and any COVID-related delays.
- Review the dilution and terms associated with the 2021 equity offerings and outstanding warrants.
- Confirm CPRIT extension, matching-fund compliance, and any consequences of discontinuing the prostate study.